RALOXIFENE
Clinical Indication
Primary prevention of osteoporotic fragility in menopausal women
Comments
Not recommended in NICE TA 160
Date of classification
July 2018
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.